Global Trust Asset Management LLC Sells 2,409 Shares of AbbVie Inc. $ABBV

Global Trust Asset Management LLC reduced its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 75.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 785 shares of the company’s stock after selling 2,409 shares during the period. Global Trust Asset Management LLC’s holdings in AbbVie were worth $179,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Evolution Wealth Management Inc. purchased a new stake in AbbVie in the second quarter worth $26,000. Chelsea Counsel Co. purchased a new stake in shares of AbbVie during the third quarter valued at $26,000. Westend Capital Management LLC purchased a new stake in shares of AbbVie during the fourth quarter valued at $29,000. Texas Capital Bancshares Inc TX bought a new position in shares of AbbVie in the third quarter worth about $31,000. Finally, Caitlin John LLC bought a new position in shares of AbbVie in the third quarter worth about $33,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

ABBV has been the subject of a number of research analyst reports. The Goldman Sachs Group reiterated a “neutral” rating and set a $223.00 price objective on shares of AbbVie in a report on Wednesday, January 28th. Royal Bank Of Canada began coverage on shares of AbbVie in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 target price on the stock. Berenberg Bank set a $275.00 target price on shares of AbbVie in a research report on Tuesday, January 20th. BMO Capital Markets reaffirmed an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $253.15.

AbbVie Price Performance

Shares of AbbVie stock opened at $208.79 on Friday. The stock has a market cap of $369.17 billion, a price-to-earnings ratio of 88.47, a PEG ratio of 0.73 and a beta of 0.38. The firm’s 50-day moving average is $221.58 and its two-hundred day moving average is $224.47. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same quarter in the previous year, the business posted $2.16 EPS. The company’s quarterly revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. AbbVie’s dividend payout ratio is currently 293.22%.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.25% of the stock is currently owned by company insiders.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.